+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
P

Actively Recruiting

Researchers are evaluating the effect of dalcetrapib on cardiovascular risk in people recently hospitalized for acute coronary syndrome ACS who have a specific genetic profile AA genotype. This phase 3, randomized, double-blind, placebo-controlled study focuses on adults aged 45 years and older, aiming to assess the time to first occurrence of fatal or non-fatal myocardial infarction over an average of 30 months from randomization. The study will continue until around 200 participants experience a primary event, or until stopped at an interim analysis. Participants will be randomly assigned to receive either dalcetrapib 600 mg daily, two 300 mg tablets or matching placebo tablets once daily. Screening includes genetic testing for the AA genotype using a specialized Genotype Assay Test. Enrollment can begin during hospitalization or after discharge, but randomization must occur within 12 weeks of the ACS event. After randomization, follow-up visits will be virtual when possible or in clinic every three months until the study ends. Assessments will continue every three months for participants who stop the study medication early. Participants will undergo medical history review and genetic testing before enrollment. During the study, researchers will monitor cardiovascular events such as heart attacks and strokes through regular assessments every three months. Safety evaluations and collection of study endpoints will continue for the duration of participation, which may last approximately 30 months or until the study stops. This includes ongoing monitoring for adverse effects and overall health status.

Age: 45Years +All GendersPhase 3
231 locations
R

Actively Recruiting

Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations. All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices. Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.

Age: 18Years +All Genders
134 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Researchers are evaluating whether up to ten consecutive 24-hour treatments with the Selective Cytopheretic Device SCD can improve survival in patients with Acute Kidney Injury AKI who need continuous kidney replacement therapy CKRT. The study compares the use of SCD plus standard CKRT to CKRT alone to see if it reduces the need for long-term dialysis. This pivotal randomized controlled trial will include about 339 patients in intensive care units across 30 US sites. Participants will be assigned to one of two groups one group will receive up to ten 24-hour treatments using the SCD connected to their existing CKRT circuit along with standard care, while the other group will receive standard CKRT care alone. The SCD is a device designed to modulate inflammation by binding activated white blood cells during CKRT using regional citrate anticoagulation. Treatments occur sequentially over the study period. During the study, participants will be monitored for survival and dialysis dependency at 90 days, as well as dialysis dependence at 1 year, ICU-free days within the first 28 days, and mortality at 28 days. The trial includes assessments related to kidney function and patient outcomes over time. Participation involves regular monitoring during ICU care, with results informing the safety and effectiveness of adding SCD therapy to standard CKRT. The study is expected to continue until June 2027.

Age: 18Years +All GendersPhase Not Applicable
36 locations
S

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 combined with chemotherapy in people with advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not received prior treatment for their advanced disease. This Phase 23 trial aims to evaluate the safety and effectiveness of PF-08634404 with chemotherapy compared to an approved treatment nivolumab plus chemotherapy for this type of cancer. Participants receive PF-08634404 or nivolumab intravenously along with chemotherapy in repeated treatment cycles. The study has two parts the first part focuses on assessing safety and response to the study medicine combined with chemotherapy, while the second part compares the study medicine plus chemotherapy to nivolumab plus chemotherapy to see which treatment works better. During the trial, participants undergo medical tests to monitor safety, treatment response, and cancer progression using established criteria. Researchers measure outcomes such as objective response rate, progression-free survival, overall survival, and quality of life over approximately four years. Adverse events, laboratory results, and drug concentrations are also tracked throughout treatment and for 90 days after the last intervention.

Age: 18Years +All GendersPhase 2Phase 3
102 locations
T

Actively Recruiting

Researchers are evaluating an experimental procedure of delivering verapamil directly into arteries for patients who have had an acute ischemic stroke. This study focuses on testing the safety of intra-arterial verapamil, a drug commonly used to treat blood vessel spasms, and how it affects recovery after stroke. The trial is limited to patients who have already received a mechanical thrombectomy as part of their standard care. Participants are randomly assigned to receive one of two doses of verapamil 10 mg or 20 mg administered intra-arterially following the mechanical thrombectomy procedure. This randomized, interventional study compares these two treatment groups to explore how the different doses impact patient outcomes and safety. During the study, participants will be monitored for bleeding complications and serious adverse events, including death, over a three-month period. Functional outcomes will be assessed at 30 and 90 days, and neuroimaging will be performed at 180 and 365 days. Researchers will track recovery progress and safety through these evaluations, with an overall follow-up period extending up to one year.

Age: 18Years - 80YearsAll GendersPhase 1Phase 2
3 locations